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Strategies to target angiogenesis include inhibition
of the vessel-stabilizing properties of vascular peri-
cytes. Pericyte depletion in early-stage non-hypoxic
tumors suppressed nascent angiogenesis, tumor
growth, and lung metastasis. In contrast, pericyte
depletion in advanced-stage hypoxic tumors with
pre-established vasculature resulted in enhanced
intra-tumoral hypoxia, decreased tumor growth,
and increased lung metastasis. Furthermore, deple-
tion of pericytes in post-natal retinal blood vessels
resulted in abnormal and leaky vasculature. Tumor
transcriptome profiling and biological validation re-
vealed that angiopoietin signaling is a key regulatory
pathway associated with pericyte targeting. Indeed,
pericyte targeting in established mouse tumors
increased angiopoietin-2 (ANG2/Angpt2) expres-
sion. Depletion of pericytes, coupled with targeting
of ANG2 signaling, restored vascular stability in mul-
tiple model systems and decreased tumor growth
and metastasis. Importantly, ANGPT2 expression
correlated with poor outcome in patients with breast
cancer. These results emphasize the potential utility
of therapeutic regimens that target pericytes and
ANG2 signaling in metastatic breast cancer.INTRODUCTION
Angiogenesis that accompanies tumor progression provides
cancer cells with a means to meet their increased demand for
oxygen and nutrients and may also provide a route for cancer
cell spread to distal tissues (Folkman, 2002; Zetter, 1998). The
complexity of blood vessel growth regulation in tumors may
partake in offering adaptive mechanisms to promote rapid emer-1066 Cell Reports 10, 1066–1081, February 24, 2015 ª2015 The Authgence of resistance mechanisms in response to anti-angiogenic
therapies, thereby limiting their efficacy (Vasudev and Reynolds,
2014). Inhibition of angiogenesis has been shown to suppress
metastasis in some experimental tumors (Folkman, 2002; Kirsch
et al., 2000; Mazzieri et al., 2011; O’Reilly et al., 1994, 1997;
Weidner et al., 1991), whereas in other studies it has been asso-
ciated with enhanced intratumoral hypoxia and increased local
tumor invasion and frequency of metastasis (Cooke et al.,
2012; Ebos et al., 2009; Pa`ez-Ribes et al., 2009). Previously,
we reported that the depletion of pericytes in established tumors
impaired the neovascularization response and suppressed tu-
mor growth, but enhanced tumor hypoxia and cancer cell spread
to target organs ofmetastasis (Cooke et al., 2012).While pericyte
coverage in established tumor blood vessels may function as a
gatekeeper of metastasis, the molecular mechanisms mediating
the increased frequency of metastasis after pericyte targeting
remain poorly characterized.
Pericytes are important regulators of angiogenesis and
vascular stability in both developmental and pathological con-
texts (Armulik et al., 2005, 2011; Bergers and Song, 2005; Hirschi
and D’Amore, 1996). These specialized perivascular mesen-
chymal cells are embedded in the basement membrane of blood
vessels (Armulik et al., 2011; Strasser et al., 2010) and secrete
pro-angiogenic factors at the onset of angiogenesis (Bergers
and Song, 2005; Bergers et al., 2003; Lu et al., 2007; Sennino
et al., 2007; Song et al., 2005), while also establishing quies-
cence of endothelial cells and stabilizing mature blood vessels
(Benjamin et al., 1998; Greenberg et al., 2008; Hammes et al.,
2002; Nasarre et al., 2009; Orlidge and D’Amore, 1987). Such
apparently opposed functions of pericytes are controlled by
the evolving pericyte-endothelial cell crosstalk that occurs dur-
ing tumor angiogenesis. Pericyte-endothelial cell signaling in-
volves multiple pathways, including angiopoietin signaling
(Armulik et al., 2005; Armulik et al., 2011). At its core, Angiopoie-
tin-1 (ANG1/Angpt1) and angiopoietin-2 (ANG2/Angpt2) are
ligands for the endothelial receptor TIE2. ANG1 is mainly
secreted by pericytes, fibroblasts, and cancer cells (Buchanan
et al., 2012) and plays a key role in regulating blood vesselors
permeability. ANG1 also signals to enhance blood vessel stabil-
ity by increasing the number of vessel-associated pericytes, i.e.,
pericyte coverage (Augustin et al., 2009; Fuxe et al., 2011; Gaen-
gel et al., 2009; Thurston et al., 1999, 2000). ANG2, which is
largely produced by activated endothelial cells, antagonizes
ANG1 and destabilizes blood vessels by promoting pericyte
detachment and initiating endothelial cell sprouting (Augustin
et al., 2009; Scharpfenecker et al., 2005; Thomas and Augustin,
2009). Hypoxia increases ANG2 expression (Kelly et al., 2003;
Oh et al., 1999; Rigamonti et al., 2014; Skuli et al., 2012) and
ANG2 induces abnormal angiogenesis in the presence of
VEGF-A (Augustin et al., 2009; Lobov et al., 2002; Thomas and
Augustin, 2009). ANG2 blockade was reported recently to
limit the onset of tumor resistance to VEGF-A signaling inhibition
in RIP1-Tag2 pancreatic neuroendocrine tumors (Rigamonti
et al., 2014).
To gain a better understanding of pericytes and pericyte-
endothelial cell interactions and signaling in blood vessel
formation, we performed experiments using genetic and phar-
macologic targeting of pericytes at various stages of tumor
and developmental (retinal) angiogenesis. In an effort to unravel
the mechanisms of resistance to anti-vascular therapies, we
focused on elucidating the regulatory cellular signaling pathways
and functional contribution of pericytes to blood vessel forma-
tion during tumor progression.
RESULTS
Coverage and Functional Role of Pericytes Evolve
during Tumor Progression
Anti-PDGFRb and NG2 antibodies have been used to label peri-
cytes (Song et al., 2005). Time-course analysis of pericyte label-
ing in orthotopically implanted 4T1 mouse mammary tumors
showed PDGFRb+ pericytes starting 4 days after injection of
cancer cells (d4). PDGFRb+ pericyte numbers increased as
the tumor grew (d7, d13–15, d26), and their proportion relative
to NG2+ pericytes was higher in early-stage non-hypoxic
(smaller) tumors when compared to late-stage hypoxic tumors
(Figures 1A, 1B, and S1A). Here, we refer to non-hypoxic tu-
mors as early-stage and hypoxic tumors as late stage. Fewer
NG2+ pericytes, compared to PDGFRb+ pericytes, were
observed in the early-stage tumors, and the overlap of NG2
and PDGFRb expression increased as tumors grew, resulting
in a gradual increase in the PDGFRb+/NG2+ double-positive
cells with tumor progression (Figures 1A, 1B, and S1A). Thus,
growing tumors present with dynamic pericyte coverage
defined by sequential and partly overlapping PDGFRb and
NG2 expression.
To functionally address the role of pericytes at different stages
of tumor progression, 4T1 breast cancer cells were injected
orthotopically into mammary fat pads of NG2-tymidine kinase
(TK), PDGFRb-TK, or wild-type (WT) control mice. We previously
showed that daily ganciclovir (GCV) administration specifically
depletes proliferating NG2+ and PDGFRb+ pericytes in NG2-TK
and PDGFRb-TK mice, respectively (Cooke et al., 2012). Deple-
tion of 75.4% of PDGFRb+ pericytes (Figures 1C and S1B) in
advanced-stage tumors (initiated when the average tumor
burden was greater than 500 mm3 and intratumoral hypoxiaCell Rclearly detected (Figure S1C)) significantly slowed tumor growth
(Figure 1D). We previously reported that depletion of NG2+ peri-
cytes in advanced-stage tumors also decreased tumor growth
(Cooke et al., 2012).
Depleting pericytes at an advanced tumor stage in NG2-TK
and PDGFRb-TK mice decreased the tumor volume by 60%
(Cooke et al., 2012) and 25% (Figure 1D), respectively, and
significantly increased the lung metastatic burden (Figure 1E;
Cooke et al., 2012). In contrast, pericyte depletion early during
tumor growth (Figures 1F and S1B) and prior to the onset of
intratumoral hypoxia (Figure S1C) reduced the tumor mass
by 36% and 72% in NG2-TK and PDGFRb-TK mice, respec-
tively (Figures 1F and S1D), but significantly decreased the
incidence of lung metastasis only in PDGFRb-TK mice (Figures
1G and S1E). The difference in the lung metastatic burden
noted in the early pericyte depletion setting between NG2-TK
and PDGFRb-TK mice may be due to the important contribu-
tion of PDGFRb+ pericytes to tumor angiogenesis at early
stages of tumor growth, when NG2+ pericytes are still scarce
(Figures 1A and 1B). PDGFRb+ pericyte depletion did not affect
metastasis in an experimental model of metastatic lung
colonization after intravenous injection of 4T1 cancer cells
(Figure S1F).
Together, the aforementioned data indicate that PDGFRb+
pericytes broadly control metastasis of cancer cells at both early
and late stages of tumor progression. We therefore focused sub-
sequent studies on PDGFRb-TK mice and pharmacological tar-
geting of PDGFRb signaling.
Pericyte Depletion in Advanced-Stage Tumors Is
Associated with Compromised Blood Vessel Stability
and Enhanced Intratumoral Hypoxia
CD31 labeling of tumor blood vessels was significantly
reduced in 4T1 tumors in both early and late pericyte deple-
tion settings (Figure S1G). Intratumoral hypoxia, assayed by
immunolabeling for pimonidazole adduct formation following
injection of hypoxyprobe, was significantly reduced upon early
depletion of pericytes (Figure S1H). In contrast, the smaller tu-
mors in PDGFRb-TK mice in the late pericyte depletion setting
displayed significantly enhanced intratumoral hypoxia
compared to WT control tumors (Figure S1H). The increased
intratumoral hypoxia noted in the late pericyte depletion
setting was associated with an increase in vascular leakage
as determined by systemic fluorescein isothiocyanate (FITC)-
dextran permeability studies (Figure 1H). A similar degree of
permeability was noted in the tumor-associated blood vessels
of mice subjected to early pericyte depletion (Figure 1H). The
blood vessels in the late depletion setting were deficient in
desmin+ cells, representing mature pericytes in structurally
stable vessels (Chan-Ling et al., 2004; Kurz et al., 2008;
Song et al., 2005; von Tell et al., 2006), suggesting that these
vessels were less stable (Figure 1I). The increased intratu-
moral hypoxia in these tumors was accompanied by
enhanced epithelial-to-mesenchymal transition (EMT) in can-
cer cells, as determined by increased numbers of CK8+ can-
cer cells acquiring mesenchymal gene expression (aSMA-pos-
itive), indicative of enhanced cancer cell invasiveness
(Figure S1I).eports 10, 1066–1081, February 24, 2015 ª2015 The Authors 1067
(legend on next page)
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Differential Effects of Pericyte Depletion on Early and
Late Retinal Development
We utilized the retinal vasculature as a model system to further
characterize the dynamic functional contributions of PDGFRb+
pericytes to developmental angiogenesis (Figure 2A). In mouse
neonatal pups, retinal blood vessels start forming after birth
(P0) and extend from the center to the periphery in an organized
network of branches and sprouts, providing an excellent model
system to study developmental angiogenesis spatiotemporally
(Stahl et al., 2010). To determine the effect of pericyte depletion
at early stages of retinal angiogenesis, GCV treatment of
PDGFRb-TK or WT littermate pups was started on the day of
birth (P0). Treatment was continued until P5, when the pups
were euthanized and the retinas harvested. To assess the effect
of pericyte depletion at a later stage of development, when the
retina vasculature was partially established, GCV treatment of
PDGFRb-TK or WT littermate pups was initiated at P4 and
continued until P9. We noted that very few blood vessels devel-
oped in retinas when pericytes were depleted early in
PDGFRb-TK pups compared to WT littermates (Figures 2B and
S2A). The lack of type IV collagen immunolabeling, which iden-
tifies the vascular basement membrane in the retinas, indicated
that the lack of blood vessels after early PDGFRb+ pericyte
depletion was not due to vessel regression but rather impaired
angiogenesis (Figure S2B).
When pericyte depletion was delayed, we noted unperturbed
blood vessel formation and sprouting angiogenesis, with blood
vessels reaching the periphery of the retina (Figures 2C and
2D). In this setting, isolectin B4 staining showed that, although
the microvascular area was not detectably affected (Figure 2E),
blood vessel branching was significantly reduced (Figure 2F).
Severe vascular leakage in both the central remodeling zone
and peripheral front of the expanding inner vascular plexus
(shown by 70 kDa FITC-dextran perfusion) was apparent after
late pericyte depletion (Figures 2G and S2C). The pericyte-
depleted blood vessels also appeared dilated, with an enlarged
vessel diameter allowing increased perfusion of 2,000 kDa FITC-
dextran (Figure S2D). Together, these findings indicate differen-Figure 1. Pericyte Depletion at Early and Late Stages of Tumor Progre
(A) Double immunolabeling for PDGFRb and NG2 (pericytes markers) in 4T1 tum
orthotopic injection. Scale bar represents 25 mm.
(B) Quantification of NG2+ and PDGFRb+ cells in individual 4T1 orthotopic tumor
double-positive cells are reported with 100% reflecting all of the NG2+ and PDG
(C) Quantification of the relative PDGFRb+ area in tumors with early and late P
PDGFRb-TK late (TK, late), n = 4.
(D) Tumor volume measurements over time, late PDGFRb+ pericyte depletion. G
(E) H&E staining of lungs fromWT and PDGFRb-TK mice with late PDGFRb+ cell d
WT, n = 11; PDGFRb-TK, n = 17. The metastatic nodules are encircled. High-magn
(F) Tumor volume measurements over time, early PDGFRb+ pericyte depletion. G
(G) H&E staining of lungs fromWT and PDGFRb-TK mice with early PDGFRb+ cell
WT, n = 12; PDGFRb-TK, n = 12. High-magnification images of metastatic nodu
(H) Representative images of tumors immunolabeled for CD31 and visualization
quantitation of FITC-dextran+ area per vessel. WT early, n = 12; PDGFRb-TK ear
(I) Representative images of tumors immunolabeled for CD31 and desmin in the
vessels associated with desmin-labeling-positive pericytes.
Solid arrowheads, vessels with desmin+ pericyte coverage; empty arrowheads, v
PDGFRb-TK late, n = 6. Scale bar represents 25 mm. Data are represented as
comparison test was used. For (C), (H), and (I), one-way ANOVA with Tukey post
used to determine statistical significance. *p < 0.05, **p < 0.01, ****p < 0.0001. n
Cell Rtial effects of depleting pericytes during the early and late stages
of retinal development.
Angiopoietin Signaling Is Differentially Modulated by
Temporal Pericyte Depletion during Tumor Progression
and Retinal Angiogenesis
To identify the potential molecular effectors that may be respon-
sible for enhanced metastasis following the late PDGFRb+
cell depletion (in contrast to early PDGFRb+ cell depletion), we
compared the gene expression profiles of tumors subjected
to either early or late PDGFRb+ cell depletion. Growth factor
signaling pathway analyses coupled to quantitative transcript
level measurements revealed that the angiopoietin signaling
pathway was deregulated both in the early and late pericyte
depletion setting, along with the VEGF, PDGF, and HGF
signaling pathways (Figure S3A). While all growth factors and
signaling targets evaluated by qRT-PCR showed a similar up-
or downregulation in both the early and late pericyte-depleted
experimental groups compared to their WT controls (Figures
S3B and S3C), Anpgt1 and Anpgt2 were uniquely deregulated
in the early versus late experimental groups (Figures 3A and
3B). Specifically, in tumors with early pericyte depletion, Angpt1
transcript levels were elevated by 5-fold while Angpt2 transcript
levels were unchanged (Figure 3A). In contrast, in tumors with
late pericyte depletion, Angpt1 transcript levels were un-
changed but Angpt2 transcript levels were elevated by 3-fold
(Figure 3B) and ANG2 protein levels by 3-fold (Figure 3C). This
significant deregulation in transcript and protein levels in early
versus late pericyte depletion was restricted to ANG1 and
ANG2 (Figures 3A and 3B). These results indicate a switch
in ANG1/ANG2 expression along with temporal targeting of
PDGFRb+ pericytes in tumors. In situ hybridization (ISH) sup-
ported the transcript data; indeed, we found no difference in
Angpt2 signal in the early pericyte depletion setting (versus con-
trols), whereas there was a marked Angpt2 signal in the late
pericyte depletion setting (Figure 3D). Angpt2 transcripts were
detected primarily in foci co-localizing with collagen IV and
CD31 immunolabeling, supporting a focal upregulation ofssion Differentially Impacts Tumor Growth and Metastasis
ors from wild-type (WT) mice at 4, 7, 10, 13, 20, and 26 days after cancer cell
s over the course of cancer progression. The relative proportion of single- and
FRb+ cells per field of view. d4, n = 3; d7, n = 3; d13–15, n = 3; d26, n = 5.
DGFRb+ pericyte depletion. WT, n = 8; PDGFRb-TK early (TK, early), n = 5;
CV treatment started when total tumor burden reached 500 mm3.
epletion and respective quantification of the percentage lung metastatic area.
ification images of metastatic nodules are shown. Scale bar represents 20 mm.
CV treatment started before total tumor burden reached 100 mm3.
depletion and respective quantification of the percentage lung metastatic area.
les are shown. Scale bar represents 20 mm.
of perfused 2,000 kDa FITC-dextran in the indicated experimental groups and
ly, n = 7; PDGFRb-TK late, n = 6. Scale bar represents 25 mm.
indicated experimental groups and quantification of the percentage of CD31+
essels without desmin+ pericyte coverage. WT n = 6; PDGFRb-TK early, n = 5;
the mean ± SEM. In (D) and (F), two-way ANOVA with Bonferroni’s multiple
hoc analysis was used. Unless otherwise noted, unpaired two-tailed t test was
s, not significant. See also Figure S1.
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Figure 2. Early, P0–P5, and Late, P4–P9, Pericyte Depletion Differentially Alter Developmental Angiogenesis in the Mouse Retina
(A) Schematic representation of stage-specific pericyte depletion in the development of the retina vasculature.
(B) Isolectin B4 staining of retinas from P5 WT and PDGFRb-TK pups treated with GCV from P0 to P5 (early depletion). Scale bar represents 500 mm; inset scale
bar represents 100 mm. Dashed arrow shows the extent of vessel coverage in WT retina at P5 with respect to the edge of the retina (solid arrow).
(C and D) Isolectin B4 staining of retinas from WT and PDGFRb-TK mice treated with GCV from P4 to P9 (late depletion). Scale bars represent 500 mm (C) and
100 mm (D).
(E) Quantitation of the isolectin B4+ area/field (vessel area). WT, n = 4; PDGFRb-TK, n = 3.
(F) Quantitation of the number of branch points/100 mm2. WT, n = 4; PDGFRb-TK, n = 3.
(G) Isolectin B4 staining and visualization of 70 kDa FITC-dextran in WT and PDGFRb-TK mice treated with GCV from P4 to P9 and quantitation of FITC-dextran+
area per vessel. WT, n = 3; PDGFRb-TK, n = 5. Scale bar represents 100 mm.
Data are represented as the mean ± SEM. Unpaired two-tailed t test was used to determine statistical significance. *p < 0.05, **p < 0.01. ns, not significant. See
also Figure S2.Angpt2 in endothelial cells (Figures 3E and 3F). While most
blood vessels displayed high levels of Angpt2 (Figure 3E, red ar-
rowheads), a few blood vessels lacked Angpt2 expression (Fig-
ure 3E, white arrowheads).
Differential expression of Angpt1 and Angpt2 associated with
pericyte depletion was also analyzed in the retina angiogenesis
model. Late depletion of retinal pericytes (P4–P7) showed un-
changed Angpt1 transcript levels, whereas Angpt2 expression
was increased (Figure 3G). Overall, these results indicate an in-
versed ANG1/ANG2 expression pattern in association with tem-
poral targeting of PDGFRb+ pericytes during both tumor growth
and retinal angiogenesis.
Anti-ANG2 Antibody Treatment Restores the Integrity of
Pericyte-Depleted Leaky Blood Vessels and Reduces
Metastasis
To determine whether the increase in lung metastasis observed
in 4T1 mammary tumor-bearing PDGFRb-TK mice was due to1070 Cell Reports 10, 1066–1081, February 24, 2015 ª2015 The Authincreased ANG2 expression in tumors with late pericyte deple-
tion, we performed rescue experiments using a murinized anti-
ANG2 neutralizing antibody (Srivastava et al., 2014). Control
mice were treated with an isotype-matched immunoglobulin G
(IgG) antibody. In WT mice without pericyte depletion, anti-
ANG2 only moderately reduced tumor growth rate (Figure 4A).
Pericyte depletion was initiated when tumor burden reached
500 mm3 of volume, and this produced a significant reduction
in tumor growth rate (Figure 4A). Although the anti-ANG2 anti-
body did not affect the tumor growth rate in pericyte-depleted
tumors (Figure 4A), we observed a significant reduction in the fre-
quency of lungmetastasis (Figures 4B and 4D). Specifically, lung
metastasis trended toward a decrease in WT mice treated with
anti-ANG2, and the increased lung metastasis in PDGFRb-TK
mice was abated to levels observed in WT mice treated with
the anti-ANG2 antibody (Figures 4B and 4D).
Next, we assayed the impact of anti-ANG2 treatment on
vascular leakage and intratumoral hypoxia. We found thators
Figure 3. Angiopoietin-1 and Angiopoietin-2 Expression Is Differentially Modulated by Pericyte Depletion in a Tumor-Stage-Dependent
Manner
(A and B) Transcript levels of Angpt1 (A) and Angpt2 (B) in 4T1 tumors from WT and PDGFRb-TK mice with early and late pericyte depletion. Angpt1: WT early,
n = 6; PDGFRb-TK early, n = 6;WT late, n = 5; PDGFRb-TK late, n = 7.Angpt2: WT early, n = 6; PDGFRb-TK early, n = 4;WT late, n = 5; PDGFRb-TK late, n = 7. The
control group (WT) was arbitrarily set to 1, unpaired one-tailed t test.
(C) ANG2 protein levels in tumors from WT (n = 4) and PDGFRb-TK (n = 4) mice with late pericyte depletion.
(D) Angpt2 in situ hybridization on the frozen section of 4T1 tumors fromWT and PDGFRb-TKmice with either early or late pericyte depletion and quantification of
Angpt2+ area/field of view. WT early, n = 6; PDGFRb-TK early, n = 4; WT late, n = 6; PDGFRb-TK late, n = 5. Scale bar represents 50 mm. One-way ANOVA was
used to determine statistical significance.
(E) Angpt2 in situ hybridization followed by collagen IV immunolabeling in tumors from PDGFRb-TK mice with late pericyte depletion. Red arrowheads, Angpt2/
collagen IV double-positive vessels. White arrowheads, collagen IV positive vessels that lack Angpt2 expression. Scale bar represents 50 mm.
(F) Angpt2 in situ hybridization followed by CD31 immunolabeling in tumors from PDGFRb-TK mice (late pericyte depletion). Scale bar represents 20 mm.
(G) Transcript levels of Angpt1 and Angpt2 in retinas upon late pericyte depletion (P4-P7). Angpt1: WT, n = 4; PDGFRb-TK, n = 7.Angpt2: WT, n = 4; PDGFRb-TK,
n = 7. The control group was arbitrarily set to 1, unpaired one-tailed t test.
Data are represented as the mean ± SEM. Unless otherwise indicated, unpaired two-tailed t test was used to determine statistical significance. *p < 0.05, **p <
0.01. ns, not significant. See also Figure S3 and Table S1.
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Figure 4. Anti-ANG2 Antibody Treatment In Pericyte-Depleted Tumors Restores Vascular Integrity and Reduces Lung Metastasis
(A) Tumor volume measurements over time in indicated experimental groups (IgG: control for anti-ANG2 antibody treatment). All mice were treated with gan-
ciclovir (GCV) concurrently with the indicated treatment and treatment started when total tumor burden reached 500mm3. Two-way ANOVAwith Tukey’smultiple
comparison test was used.
(B) Quantification of the number of surface lung nodules. IgG + WT, n = 5; anti-ANG2 + WT, n = 5; IgG + PDGFRb-TK, n = 5; anti-ANG2 + PDGFRb-TK, n = 5.
(C) Quantification of the percentage lung metastatic area based on H&E staining of lung sections. IgG + WT, n = 5; anti-ANG2 + WT, n = 5; IgG + PDGFRb-TK,
n = 5; anti-ANG2 + PDGFRb-TK, n = 5.
(D) H&E staining of lungs from the indicated experimental groups. The metastatic nodules are encircled. High-magnification images of metastatic nodules are
shown. Scale bar represents 20 mm.
(legend continued on next page)
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anti-ANG2 treatment in the context of PDGFRb+ pericyte deple-
tion restored the structural stability of the blood vessels, as
determined by reduced vascular leakage (Figures 4E and 4F),
restored vessel diameter (Figures S4A and S4B), and diminished
EMT program (Figures 4G, 4H, S4D, and S4E) and intratumoral
hypoxia (Figures 4I–4J). Tumor lymphangiogenesis (mostly
peri-tumoral in this model) assayed by LYVE-1 staining was un-
changed in all experimental groups (Figure S4F). Pericyte deple-
tion, with and without anti-ANG2 treatment, did not impact
vascular TIE2 expression (Figure S4G), nor tumor infiltration by
TIE2-expressing macrophages (Figure S4H), suggesting that
ANG2 upregulation in pericyte-depleted tumors acts in an auto-
crine manner to destabilize endothelial cells, and that the effect
of anti-ANG2 treatment is mediated by suppression of the imbal-
anced ANG2/TIE2 signaling without affecting TIE2 expression in
endothelial cells or macrophages. Finally, global gene expres-
sion profiling of the WT, PDGFRb-TK, and PDGFRb-TK tumors
treated with the anti-ANG2 antibody revealed impaired angio-
poietin signaling in pericyte-depleted tumors, and a gene
expression pattern partially reverted to that of WT control mice
after treatment with the anti-ANG2 antibody (Figure 4K).
Then, we analyzed ANG2 signaling induced by late PDGFRb+
cell depletion during retinal angiogenesis. Similar to the findings
in tumors, anti-ANG2 rescued the vascular phenotype observed
in the retina of PDGFRb-TK pups. The enhanced vascular
leakage at the central zone of the vascular plexus and at the
sprouting edge of the primary plexus was observed specifically
in PDGFRb-TK mice in the late-stage pericyte depletion setting;
anti-ANG2 antibody treatment re-established the retinal vessel
structural stability in PDGFRb-TK mice (Figures 5A and 5B).
Enhanced vessel diameter in PDGFRb-TK mice (Figure S3D)
was also restored by anti-ANG2 (Figure 5C). Anti-ANG2 treat-
ment did notmodify NG2+ pericyte coverage in retinal blood ves-
sels (Figures 5A and 5D). Taken together, these results indicate
that PDGFRb+ pericyte depletion promotes an ANG2-mediated
increase in vascular destabilization and permeability, both in tu-
mors and the developing retinal vasculature.
Treatment of Established Breast Tumors with Imatinib
and Anti-ANG2 Antibody Restores Blood Vessel
Structural Stability and Limits Metastasis
We previously reported that imatinib significantly reduced peri-
cyte coverage in 4T1 tumors (Cooke et al., 2012). In larger tumors
(tumor burden 500 mm3), imatinib treatment mirrored the
phenotype observed in PDGFRb-TK and NG2-TK mice, which
resulted in increased vascular leakage and intratumoral hypoxia
associated with lung-enhanced metastasis (Cooke et al., 2012).(E and F) Immunolabeling for CD31 and FITC for visualization of 2,000 kDa FITC-de
per field of view. IgG + PDGFRb-TK, n = 3; anti-ANG2 + PDGFRb-TK, n = 3. Sca
(G andH) Representative images of tumors immunolabeled for CK8 and aSMA in th
cells per visual field. WT, n = 3; PDGFRb-TK, n = 3; anti-ANG2+PDGFRb-TK, n =
(I and J) Immunolabeling of hypoxyprobe (pimonidazole adduct formation) in the
area. IgG + WT, n = 3; anti-ANG2 + WT, n = 3; IgG + PDGFRb-TK, n = 4; anti-AN
(K) Heatmap of the differentially regulated genes in the angiopoietin signaling path
the mean ± SEM.
Unless otherwise noted, one-way ANOVA with Tukey post hoc analysis was used
0.0001. See also Figure S4.
Cell RTo determine whether imatinib and ANG2 neutralization may
synergistically decrease primary tumor burden and lung metas-
tasis, we treated 4T1 tumor-bearing mice with a single agent
(imatinib) or a combination therapy (imatinib and anti-ANG2).
Control mice were treated with saline (PBS) and control IgG.
Single therapy with imatinib reduced primary tumor growth
compared to control mice (Figure 6A), as previously reported
(Cooke et al., 2012). Combination therapy with imatinib and
anti-ANG2 antibody further increased inhibition of primary tumor
growth when compared to imatinib monotherapy (Figure 6A).
Imatinib treatment in established 4T1 tumors resulted in an in-
crease in lung metastasis (Figures 6B and 6C; Cooke et al.,
2012); however, the combination therapy resulted in a significant
reduction of lung metastasis when compared to imatinib only
(Figures 6B and 6C). Tumor necrosis was increased by anti-
ANG2 (Figure 6D), as previously reported (Thomas et al., 2013),
and may contribute to the stalled tumor growth (Figure 6A).
Histological findings in the heart, bowel, kidney, and pancreas
were unremarkable in control, imatinib alone, and imatinib/anti-
ANG2 combination therapy (Figure S5A). A liver metastasis
was noted in one of the mice treated with imatinib (in agreement
with enhanced metastatic disease after imatinib monotherapy),
and enlarged spleen with follicular expansion characteristic of
tumor bearing mice was observed in all mice (Figure S5A).
Intratumoral hypoxia and vascular leakage were enhanced in
tumors treated with imatinib (Figures 6E and 6F; Cooke et al.,
2012). Concomitant anti-ANG2 and imatinib treatment reduced
intratumoral hypoxia (Figure 6E), vascular leakage (Figure 6F),
and vessel diameter (Figures S4A and S4C). Additional targets
of imatinib, such as c-Kit and Abl1, were unchanged in imati-
nib-treated mice (Figure S5B; Cooke et al., 2012). Collectively,
these results indicate that the anti-metastatic effects of ANG2
blockade may be due, at least in part, to improved vascular sta-
bilization and decreased tumor hypoxia.
Normalization of Angiopoietin Signaling in PDGFRb+
Pericyte-Depleted Tumors Promotes Desmin+ Pericyte
Coverage and Increases Endothelial Cell-Cell Tight
Junctions
To determine the mechanistic underpinning of ANG2 neutraliza-
tion in decreasing destabilized blood vessels in the context of
genetic (PDGFRb-TK mice, see Figures 4 and 5) or pharmaco-
logic (imatinib, see Figure 6) targeting of PDGFRb+ pericytes,
we evaluated the differential expression of the mature pericyte
marker desmin (Des). Gene expression profiling showed a
sustained decrease in Pdgfrb transcript levels in tumors with
PDGFRb-TK mice despite anti-ANG2 antibody treatmentxtran in the indicated experimental groups and quantification of the FITC+ area
le bar represents 50 mm. Unpaired two-tailed t test was used.
e indicated experimental groups and quantification of the relative CK8+ aSMA+
3. Scale bar represents 10 mm.
indicated experimental groups and quantitation of relative percentage hypoxic
G2 + PDGFRb-TK, n = 3. Scale bar represents 500 mm.
ways in the tumors of indicated experimental groups. Data are represented as
to determine statistical significance. *p < 0.05, **p < 0.01, ***p < 0.001, ****p <
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Figure 5. Anti-ANG2 Antibody Treatment Reduces Vascular Leakage of Retinas with Late Pericyte Depletion
(A) Immunolabeling for NG2, isolectin B4 staining, and visualization of 2,000 kDa FITC-dextran of retinas from WT and PDGFRb-TK pups treated with either
control IgG or anti-ANG2 antibody from P4 to P9 (late pericyte depletion). All mice were treated with GCV. Scale bar represents 200 mm.
(B) Quantification of FITC-dextran+ area per vessel. IgG + WT, n = 3; anti-ANG2 + WT, n = 3; IgG + PDGFRb-TK, n = 3; anti-ANG2 + PDGFRb-TK, n = 5.
(C) Isolectin B4 staining of the retina in the indicated experimental groups and quantification of the mean vessel diameter. IgG +WT, n = 3; anti-ANG2 +WT, n = 4;
IgG + PDGFRb-TK, n = 5; anti-ANG2 + PDGFRb-TK, n = 5. Representative vessel diameters are listed. Scale bar represents 40 mm.
(D) Quantification of Isolectin B4+ vessels associated with NG2+ pericytes coverage. IgG + WT, n = 3; anti-ANG2 + WT, n = 4; IgG + PDGFRb-TK, n = 3; anti-
ANG2 + PDGFRb-TK, n = 5.
Data are represented as the mean ± SEM. One-way ANOVA with Tukey post hoc analysis was used to determine statistical significance. *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001.(Figure 7A). ANG2 blockade limited the decrease in Des tran-
script levels observed in tumors of PDGFRb-TK compared to
control mice (Figure 7A). Desmin immunolabeling in proximity
to CD31 vascular labeling indicated a significant increase in des-
min+ mature pericyte coverage of tumor vessels in PDGFRb+1074 Cell Reports 10, 1066–1081, February 24, 2015 ª2015 The Authpericyte-depleted tumors treated with the anti-ANG2 antibody
(Figure 7B). ANG2 blockade also promoted desmin+ pericyte
coverage of tumor vessels in WT mice without PDGFRb+ peri-
cyte depletion (Figure 7B). These results show that anti-ANG2
treatment upregulated the expression of desmin and increasedors
Figure 6. Imatinib and Anti-ANG2 Antibody Treatments Synergistically Control Tumor Growth and Metastasis
(A) Tumor volume measurements over time in indicated experimental groups (IgG: control for anti-ANG2 treatment, PBS: control for imatinib). Treatment started
when total tumor burden reached 500 mm3. Two-way ANOVA with Bonferroni’s multiple comparison test was used.
(B) Quantification of the percentage lung metastatic area. IgG + PBS, n = 8; IgG + imatinib, n = 8; anti-ANG2 + imatinib, n = 8.
(C) H&E staining of lungs from the indicated experimental groups. The metastatic nodules are encircled. High-magnification images of metastatic nodules are
shown; scale bar represents 20 mm.
(D) Quantification of the percentage tumor necrotic area. IgG + PBS, n = 5; IgG + imatinib, n = 5; anti-ANG2 + imatinib, n = 5.
(E) Immunolabeling of hypoxyprobe (pimonidazole adduct formation) in the indicated experimental groups and quantitation of percentage hypoxic area. IgG +
PBS, n = 5; IgG + imatinib, n = 5; anti-ANG2 + imatinib, n = 5. Scale bar represents 500 mm.
(F) Immunolabeling for CD31 and visualization of 2,000 kDa FITC-dextran in the indicated experimental groups and quantification of the FITC-dextran+ area per
vessel. IgG + PBS, n = 3; IgG + imatinib, n = 5; anti-ANG2 + imatinib, n = 5. Scale bar represents 50 mm.
Data are represented as the mean ± SEM. Unless otherwise noted, one-way ANOVA with Tukey post hoc analysis was used to determine statistical significance.
*p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S6.
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Figure 7. Neutralization of ANG2 in Pericyte-Depleted Tumors Re-establish Mature Pericyte Vessel Coverage and Endothelial Cell-Cell Tight
Junction in Association with Restored CXCR4 and VEGF Signaling Pathways
(A) Color-coded table listing the fold change in transcript levels of Pdgfrb and Des (desmin) based on global gene expression profiling of tumors from mice in the
indicated experimental groups.
(B) Representative images of tumors immunolabeled for CD31 and desmin in the indicated experimental groups and quantification of the percentage CD31+
vessels associated with desmin+ pericytes. IgG + WT, n = 3; anti-ANG2 + WT, n = 3; IgG + PDGFRb-TK, n = 4; anti-ANG2 + PDGFRb-TK, n = 4. Scale bar
represents 25 mm.
(C) Heatmaps reflecting the differentially regulated genes in tumors of indicated experimental groups in each of the indicated pathways.
(legend continued on next page)
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vascular coverage by mature pericytes, in spite of the loss of
Pdgfrb expression caused by genetic targeting of PDGFRb+
pericytes.
Global gene expression signaling revealed partially restored
VEGF family-ligand-receptor interactions and CXCR4 signaling
pathways after anti-ANG2 treatment (Figure 7C). Transcriptome
analyses showed that expression of Cxcr4 was increased in tu-
mors from PDGFRb-TK compared to WT control mice (both
treated with control IgG); these results were validated by qRT-
PCR (Figure 7D). Cxcr4 expression in tumors from PDGFRb-TK
mice treated with anti-ANG2 antibody was restored to levels
observed in WT tumors (Figure 7D). These results suggest a
rescued vessel permeability defect following anti-ANG2 anti-
body treatment. Angpt2 transcript levels were elevated in
PDGFRb-TK tumors, corroborating our earlier observation (Fig-
ures 3A–3C). Anti-ANG2 treatment did not suppress the tran-
scription of Angpt2, consistent with previous findings (Mazzieri
et al., 2011; Rigamonti et al., 2014), indicating that the therapeu-
tic effect of antibody-mediated ANG2 blockade is mediated
through downstream signaling rather than via transcriptional
feedback downregulation of Angpt2 (Figure 7D). These tran-
scriptomic analyses support the notion that increased Angpt2
expression in tumors with late pericyte depletion may compro-
mise vessel integrity via deregulation of CXCR4/CXCL12
signaling. Several studies have shown that CXCR4/CXCL12
plays a role in vascular permeability (Suri et al., 1998), endothelial
cell patterning and morphology (Strasser et al., 2010), and
transendothelial migration and metastasis of breast cancer cells
(Lee et al., 2004; Mukherjee and Zhao, 2013; Mu¨ller et al., 2001).
We also observed restored ZO-1 expression (a marker for endo-
thelial tight junction) in endothelial cells of tumors from
PDGFRb-TK mice treated with the anti-ANG2 antibody, similar
to levels of control tumors (WT mice treated with IgG control)
(Figure 7E).
ANGPT2 and PDGFRB Expression Correlate with Poor
Outcome in Patients with Breast Cancer
We queried the Kaplan-Meier plotter data set (Gyorffy et al.,
2012) and evaluated the survival probability of patients with
breast cancer based on their tumor transcriptomes (Figures
7F–7H). The median transcript level of ANGPT1, ANGPT2, and
PDGFRB was used to stratify 3,455 patient tumor transcrip-
tomes into high and low expression for each gene. HighANGPT1
expression was associated with improved outcome (Figure 7F).
In contrast, a significant association of high ANGPT2 expression
and poor recurrence free survival was found (Figure 7G). In addi-
tion, low PDGFRB expression was associated with poor recur-
rence free survival (Figure 7H). These analyses are in agreement
with results obtained in our mouse studies: whereas high
ANGPT1 was associated with suppressed metastasis, high(D) qRT-PCR for Angpt2 and Cxcr4 in tumors from the indicated experimenta
PDGFRb-TK, n = 5. Cxcr4: IgG + WT, n = 4; IgG + PDGFRb-TK, n = 4; anti-ANG
(E) Representative images of tumors immunolabeled for CD31 and ZO-1 in the ind
of ZO-1+ vessels. IgG + WT, n = 3; IgG + PDGFRb-TK, n = 3; anti-ANG2 + PDGF
(F–H) Kaplan-Meier plots depicting the recurrence free survival probability of patie
(H) tumor expression. HR, hazard ratio. Log-rank test was used. Data are represe
post hoc analysis was used to determine statistical significance. *p < 0.05, **p <
Cell RANGPT2was associated with enhancedmetastasis in mice (Fig-
ures 1E and 3B–3D). These results are also consistent with the
higher metastatic tumor burden noted in PDGFRb-TK mice
(low PDGFRB), in which high ANGPT2 expression was noted
(Figures 3B–3D).
DISCUSSION
Anti-angiogenic cancer therapies show efficacy but did not
realize the full potential that preclinical studies had suggested,
highlighting an unforeseen complexity of tumor neo-angiogen-
esis (Bisacchi et al., 2003; Folkman, 1972). Newly formed blood
vessels, or lack thereof, affect themetabolic status of the primary
tumor and may influence cancer cells’ metastatic potential in
addition to providing routes to metastasis (Cooke et al., 2012;
Folkman, 2002; Zetter, 1998). To shed light on the complex
and dynamic nature of pericyte-endothelial cell interactions in
various phases of tumor angiogenesis, we employed genetic tar-
geting of pericytes in non-hypoxic (early stage) or hypoxic
(advanced stage) tumors.
Our data indicated that anti-vascular therapy via depletion of
PDGFRb+ pericytes at early stages of tumor progression
reducedmetastasis, whereas targeting these cells at later stages
enhanced metastasis. The stage-specific effects are a result of
differential, dynamic PDGFRb+ pericyte interactions with endo-
thelial cells during the evolving angiogenic process. Early
PDGFRb+ pericyte depletion severely suppressed tumor angio-
genesis, blunted primary tumor growth, and reduced intratu-
moral hypoxia. The desmin+ pericyte coverage in the small,
PDGFRb+ pericyte-depleted tumors suggests that impeded
tumor angiogenesis at this early stage of tumor growth was
associated with the development of a vascular network that
adequately matched the tumor’s energetic needs with its
growth rate.
In contrast with the early pericyte depletion experiments, the
late depletion of pericytes in established primary tumors resulted
in amoderate decrease of tumor growth but was associated with
a significant increase of lung metastasis. The late pericyte-
depleted tumors displayed an overall reduction of tumor blood
vessels, with the remaining blood vessels characterized by hy-
perpermeability and poor desmin+ pericyte coverage, both likely
contributing to the increased intratumoral hypoxia and metasta-
tic dissemination. The stage-specific metastasis phenotypes
may also underscore the relative contribution of specific pericyte
subtypes to tumor angiogenesis. Our studies on early tumor
development indeed showed a differential timing for PDGFRb+
and NG2+ pericytes accumulation, with increasing overlap of
expression, suggesting that PDGFRb+ cells acquire NG2 expres-
sion. These findings may explain, at least in part, the differences
observed in early ablation of PDGFRb+ versus NG2+ cells in 4T1l groups. Angpt2: IgG + WT, n = 4; IgG + PDGFRb-TK, n = 5; anti-ANG2 +
2 + PDGFRb-TK, n = 4.
icated experimental groups and quantification of the percentage of the number
Rb-TK, n = 3. Scale bar represents 25 mm.
nts with breast cancer (n = 3,455) based on Angpt1 (F), Angpt2 (G), and Pdgfrb
nted as the mean ± SEM. Unless otherwise noted, one-way ANOVA with Tukey
0.01, ***p < 0.001, ****p < 0.0001.
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tumors, whereby early ablation of NG2+ cells has minimal effects
on tumor growth and metastasis.
Our transcriptomic studies identified angiopoietin signaling
as uniquely deregulated with respect to early versus late
pericyte targeting, and we further implicated ANG2 expression
and signaling as a key mediator of the metastatic pheno-
type associated with tumor-stage-specific PDGFRb+ pericyte
depletion. Using genetic depletion of PDGFRb+ pericytes or
pharmacological targeting of PDGFRb signaling by imatinib,
we showed that the leaky vascular phenotype in these tumors
was associated with elevated ANG2 expression. Vessels with
increased ANG2 stimulation in the Rip1Tag2 transgenic mouse
model were previously characterized by reduced pericyte
coverage and were found dilated, destabilized, and highly
permeable (Fagiani et al., 2011), all of which are consistent
with our observations. Furthermore, our analyses also high-
lighted a deregulation of CXCR4/CXCL12 signaling in associa-
tion with late PDGFRb+ pericytes depletion, also in concordance
with its known implication in vessel permeability (Suri et al., 1998)
and breast cancer cell transendothelial migration andmetastasis
(Lee et al., 2004; Mukherjee and Zhao, 2013; Mu¨ller et al., 2001).
Our previous studies have shown that pericyte targeting in
established tumors leads to increased EMT associated with
increased c-MET expression in hypoxic cancer cells (Cooke
et al., 2012). The current study suggests that such increase in
c-MET expression in cancer cells could be facilitated by
enhanced hypoxia resulting from ANG2-mediated vascular
defects.
Our results indicate ANG2-mediated destabilization of sprout-
ing blood vessels in the hypoxic environment of the late pericyte
depletion setting, and high levels of Angpt2 in this settingmay be
restricted to endothelial cells in the more hypoxic regions of the
tumor. ANG2 has been associated with metastasis in melanoma
patients; indeed, increased circulating ANG2 levels were associ-
ated with tumor progression and metastasis (Helfrich et al.,
2009). The association of ANG1with metastasis has been uncer-
tain in clinical contexts (Szarvas et al., 2008). Our results indicate
that ANG1 expression is associated with decreased metastasis
and increased desmin+ pericyte coverage, and high ANGPT1
is associated with increased survival probability in surveyed
breast cancer transcriptomes.
While overexpression of ANG2 increases metastasis through
enhanced vascular permeability (Holopainen et al., 2012), block-
ing of ANG2 signaling enhances pericyte coverage of blood ves-
sels (Rigamonti et al., 2014) and strongly inhibits metastasis
(Mazzieri et al., 2011), possibly by stabilizing the tumor-associ-
ated vasculature via enhanced endothelial cell-cell junctions
(Holopainen et al., 2012) and by displacing macrophages that
assist cancer cell intravasation from the tumor blood vessels
(Mazzieri et al., 2011). Of note, anti-ANG2 suppresses both
spontaneous metastasis of primary mammary tumors and the
metastatic colonization of the lung after cancer cell seeding
(Mazzieri et al., 2011). In this regard, anti-ANG2 antibody treat-
ment was recently shown to suppress metastatic growth also
in the adjuvant (post-surgical) setting in mice, an effect mediated
via suppression of the endothelial cell proinflammatory pheno-
type at the metastatic site (Srivastava et al., 2014). While such
anti-metastatic mechanism could also be at play in our studies,1078 Cell Reports 10, 1066–1081, February 24, 2015 ª2015 The Authwe also show that ANG2 blockade concomitant to PDGFRb+
pericyte depletion during the late phases of tumor progression
provides benefit by reducing both primary tumor growth and
metastatic disease. Anti-ANG2 treatment rescued the vascular
defects induced by pericyte targeting, and imatinib and anti-
ANG2 combination therapy suppressed primary tumor growth
and controlled lung metastasis. The vascular defects associated
with pericyte targeting in retinal angiogenesis were also restored
upon anti-ANG2 therapy. ANG2 signaling inhibition enhanced
endothelial cell-cell tight junctions, and these results altogether
suggest that ANG2 signaling is central to the loss of vascular sta-
bility associated with PDGFRb+ pericyte targeting in both tumor
and developmental angiogenesis. Finally, the analysis of the tu-
mor transcriptomes of patients with breast cancer revealed a
robust correlation between recurrence-free survival and expres-
sion of ANGPT2 and PDGFRB.
Our results indicate that the enhanced cancer cell dissemina-
tion induced by targeting PDGFRb+ pericytes in advanced stage
tumors could be controlled by the administration of an anti-
ANG2 antibody. Increased intratumoral hypoxia in late-stage tu-
mors enhances ANG2 production by endothelial cells (Holash
et al., 1999; Saharinen et al., 2011), further destabilizing the tu-
mor vasculature and fueling a vicious cycle set forth by PDGFRb+
pericyte targeting. While the anti-metastatic effects of the anti-
ANG2 antibody may also be due to impaired angiogenesis and
cancer cell growth at the metastatic site, our results indicate
that its effects are also targeted to the primary tumors and their
metastatic potential. Our findings further imply that vascular
normalization and consequently improved vascular perfusion
(Augustin et al., 2009; Carmeliet and Jain, 2011a, 2011b; Jain,
2005; Li et al., 2007; Skuli et al., 2009) may be achieved by
PGDFRb+ pericyte targeting concomitant with anti-ANG2 anti-
body therapy. This strategy, if combined with chemotherapy,
may potently suppress tumor growth by enhancing chemother-
apeutic delivery while preserving the structural stability of the
tumor blood vessels, thus minimizing hypoxia-induced metasta-
tic dissemination.
EXPERIMENTAL PROCEDURES
Cells and Mice
4T1 Balb/c mammary tumor epithelial cells were obtained from ATCC and
grown in DMEM media supplemented with 10% fetal bovine serum (FBS).
PDGFRb-TK and NG2-TK Balb/c mice were previously described (Cooke
et al., 2012). Female mice, between the ages of 6 and 12 weeks, were used
for orthotopic implantation of 4T1 mammary epithelial cancer cells, as
described previously (Cooke et al., 2012). Mice received daily intraperitoneal
(i.p.) GCV injections at a 50 mg/kg body weight (BW) dose at the indicated
time points and, when indicated, also received i.p. injections of a neutral-
izing anti-ANG2 antibody (murinized LC06, Roche Diagnostics) (Srivastava
et al., 2014) or control isotype-matched IgG antibody once a week
(10 mg/kg BW in 0.2 ml PBS), or imatinib or PBS by oral gavage daily
(50 mg/kg BW in 0.1 ml). All mouse experiments were reviewed and approved
by the Institute of Animal Care and Use Committee at the Beth Israel
Deaconess Medical Center (BIDMC) and the MD Anderson Cancer Center
(MDACC). Additional experimental details are listed in the Supplemental
Experimental Procedures.
Tumor Vessel Leakage and Metastatic Burden
Mice were injected in the retro-orbital venous plexus with 100 ml of 10 mg/ml
FITC-dextran (2,000,000 MW, Sigma) 5 min prior euthanasia. Tumorors
sections from optimum cutting temperature (OCT)-embedded tumors were
immunostained for CD31. FITC-dextran was visualized either directly by fluo-
rescent microscopy under the green fluorescent filter or by immunostaining
with anti-FITC antibody and a FITC-conjugated secondary antibody. FITC-
dextran is quantified by ImageJ area fraction analysis. Multiple sections/tu-
mor were analyzed at original magnification 340 with n R 3 tumors/group.
Histological assessment and quantitation of the metastatic and tumor necro-
sis areas are described in the Supplemental Experimental Procedures.
Microarray Analysis and qPCR Analyses
Microarray analysis was performed using Mouse Ref8 or Ref6 Gene Expres-
sion BeadChip (Illumina). Details for microarray samples, qRT-PCR analyses,
and primer sequence information are listed in the Supplemental Experimental
Procedures and Table S1.
Statistical Analysis
For comparison between two groups with one grouping variable, the unpaired
two-tailed Student’s t test was used. For RT-PCR analyses, the unpaired one-
tailed Student’s t test was used to compare dCt between experimental groups.
To compare multiple groups, analysis of variance (ANOVA) was used with
Prism software. For multiple groups with one grouping variable, one-way
ANOVA with multiple comparisons with Tukey correction was performed,
and, for multiple groups with two grouping variables, two-way ANOVA with
Bonferroni’s multiple comparison test was used. p < 0.05 was considered sta-
tistically significant. All data are represented as the mean with error bars cor-
responding to SEM.
ACCESSION NUMBERS
TheNCBI GEO accession number for the gene expression data reported in this
paper is GSE55785.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2015.01.035.
AUTHOR CONTRIBUTIONS
D.K., J.K., V.G.C., C.-C.W., H.S., and V.S.L. performed experiments and
analyzed data. M.D.P. provided reagents and intellectual input and edited
the manuscript. C.G. provided reagents and intellectual input. D.K. and J.K.
participated in the writing the manuscript and preparation of figures. R.K.
and V.S.L. wrote the manuscript, prepared figures, and oversaw the study
design and execution and analysis of the experiments.
ACKNOWLEDGMENTS
Wewish to thankMarkus Thomas and JoachimMuller (Roche, Penzberg, Ger-
many) for providing the anti-ANG2 antibody and Lauren Bizarro, Cristina Espi-
nosa da Silva, and Laura Gibson for genotyping and animal husbandry sup-
port. We thank Erica Lawson, Komal Vadnagara, Donna Lundy, Sergio Dias,
and Oleg Tsinkalovsky for technical support. We also wish to thank Dr. Bala´zs
Gyo¨rffy for his help in mining the KM plotter data sets. This study was primarily
supported by the NIH grant CA155370 (R.K.). R.K. is also supported by the
Cancer Prevention and Research Institute of Texas and the Metastasis
Research Center at MD Anderson Cancer Center, NIH grants CA125550,
CA155370, CA151925, and CA163191. V.S.L. is supported by the NIH/NCI
CCSG New Faculty Award P30CA016672 and UT MDACC Khalifa Bin Zayed
Al Nahya Foundation. C.G. is supported by NIH RO1 NS064583.
Received: September 29, 2014
Revised: December 2, 2014
Accepted: January 13, 2015
Published: February 19, 2015Cell RREFERENCES
Armulik, A., Abramsson, A., and Betsholtz, C. (2005). Endothelial/pericyte in-
teractions. Circ. Res. 97, 512–523.
Armulik, A., Genove´, G., and Betsholtz, C. (2011). Pericytes: developmental,
physiological, and pathological perspectives, problems, and promises. Dev.
Cell 21, 193–215.
Augustin, H.G., Koh, G.Y., Thurston, G., and Alitalo, K. (2009). Control of
vascular morphogenesis and homeostasis through the angiopoietin-Tie sys-
tem. Nat. Rev. Mol. Cell Biol. 10, 165–177.
Benjamin, L.E., Hemo, I., and Keshet, E. (1998). A plasticity window for blood
vessel remodelling is defined by pericyte coverage of the preformed endothe-
lial network and is regulated by PDGF-B and VEGF. Development 125, 1591–
1598.
Bergers, G., and Song, S. (2005). The role of pericytes in blood-vessel forma-
tion and maintenance. Neuro-oncol. 7, 452–464.
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., and Hanahan, D.
(2003). Benefits of targeting both pericytes and endothelial cells in the tumor
vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287–1295.
Bisacchi, D., Benelli, R., Vanzetto, C., Ferrari, N., Tosetti, F., and Albini, A.
(2003). Anti-angiogenesis and angioprevention: mechanisms, problems and
perspectives. Cancer Detect. Prev. 27, 229–238.
Buchanan, C.F., Szot, C.S., Wilson, T.D., Akman, S., Metheny-Barlow, L.J.,
Robertson, J.L., Freeman, J.W., and Rylander, M.N. (2012). Cross-talk be-
tween endothelial and breast cancer cells regulates reciprocal expression of
angiogenic factors in vitro. J. Cell. Biochem. 113, 1142–1151.
Carmeliet, P., and Jain, R.K. (2011a). Molecular mechanisms and clinical ap-
plications of angiogenesis. Nature 473, 298–307.
Carmeliet, P., and Jain, R.K. (2011b). Principles and mechanisms of vessel
normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Dis-
cov. 10, 417–427.
Chan-Ling, T., Page, M.P., Gardiner, T., Baxter, L., Rosinova, E., and Hughes,
S. (2004). Desmin ensheathment ratio as an indicator of vessel stability: evi-
dence in normal development and in retinopathy of prematurity. Am. J. Pathol.
165, 1301–1313.
Cooke, V.G., LeBleu, V.S., Keskin, D., Khan, Z., O’Connell, J.T., Teng, Y., Dun-
can, M.B., Xie, L., Maeda, G., Vong, S., et al. (2012). Pericyte depletion results
in hypoxia-associated epithelial-to-mesenchymal transition and metastasis
mediated by met signaling pathway. Cancer Cell 21, 66–81.
Ebos, J.M., Lee, C.R., Cruz-Munoz, W., Bjarnason, G.A., Christensen, J.G.,
and Kerbel, R.S. (2009). Accelerated metastasis after short-term treatment
with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232–239.
Fagiani, E., Lorentz, P., Kopfstein, L., and Christofori, G. (2011). Angiopoietin-1
and -2 exert antagonistic functions in tumor angiogenesis, yet both induce
lymphangiogenesis. Cancer Res. 71, 5717–5727.
Folkman, J. (1972). Anti-angiogenesis: new concept for therapy of solid tu-
mors. Ann. Surg. 175, 409–416.
Folkman, J. (2002). Role of angiogenesis in tumor growth and metastasis.
Semin. Oncol. 29 (6, Suppl 16), 15–18.
Fuxe, J., Tabruyn, S., Colton, K., Zaid, H., Adams, A., Baluk, P., Lashnits, E.,
Morisada, T., Le, T., O’Brien, S., et al. (2011). Pericyte requirement for anti-
leak action of angiopoietin-1 and vascular remodeling in sustained inflamma-
tion. Am. J. Pathol. 178, 2897–2909.
Gaengel, K., Genove´, G., Armulik, A., and Betsholtz, C. (2009). Endothelial-
mural cell signaling in vascular development and angiogenesis. Arterioscler.
Thromb. Vasc. Biol. 29, 630–638.
Greenberg, J.I., Shields, D.J., Barillas, S.G., Acevedo, L.M., Murphy, E.,
Huang, J., Scheppke, L., Stockmann, C., Johnson, R.S., Angle, N., and Cher-
esh, D.A. (2008). A role for VEGF as a negative regulator of pericyte function
and vessel maturation. Nature 456, 809–813.
Gyorffy, B., La´nczky, A., and Sza´lla´si, Z. (2012). Implementing an online tool for
genome-wide validation of survival-associated biomarkers in ovarian-cancer
using microarray data from 1287 patients. Endocr. Relat. Cancer 19, 197–208.eports 10, 1066–1081, February 24, 2015 ª2015 The Authors 1079
Hammes, H.P., Lin, J., Renner, O., Shani, M., Lundqvist, A., Betsholtz, C.,
Brownlee, M., and Deutsch, U. (2002). Pericytes and the pathogenesis of dia-
betic retinopathy. Diabetes 51, 3107–3112.
Helfrich, I., Edler, L., Sucker, A., Thomas, M., Christian, S., Schadendorf, D.,
and Augustin, H.G. (2009). Angiopoietin-2 levels are associated with disease
progression in metastatic malignant melanoma. Clin. Cancer Res. 15, 1384–
1392.
Hirschi, K.K., and D’Amore, P.A. (1996). Pericytes in the microvasculature.
Cardiovasc. Res. 32, 687–698.
Holash, J., Wiegand, S.J., and Yancopoulos, G.D. (1999). New model
of tumor angiogenesis: dynamic balance between vessel regression
and growth mediated by angiopoietins and VEGF. Oncogene 18, 5356–
5362.
Holopainen, T., Saharinen, P., D’Amico, G., Lampinen, A., Eklund, L., Sormu-
nen, R., Anisimov, A., Zarkada, G., Lohela, M., Helotera¨, H., et al. (2012).
Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions
and lung metastasis. J. Natl. Cancer Inst. 104, 461–475.
Jain, R.K. (2005). Normalization of tumor vasculature: an emerging concept in
antiangiogenic therapy. Science 307, 58–62.
Kelly, B.D., Hackett, S.F., Hirota, K., Oshima, Y., Cai, Z., Berg-Dixon, S.,
Rowan, A., Yan, Z., Campochiaro, P.A., and Semenza, G.L. (2003). Cell
type-specific regulation of angiogenic growth factor gene expression and in-
duction of angiogenesis in nonischemic tissue by a constitutively active form
of hypoxia-inducible factor 1. Circ. Res. 93, 1074–1081.
Kirsch, M., Schackert, G., and Black, P.M. (2000). Angiogenesis, metastasis,
and endogenous inhibition. J. Neurooncol. 50, 173–180.
Kurz, H., Fehr, J., Nitschke, R., and Burkhardt, H. (2008). Pericytes in the
mature chorioallantoic membrane capillary plexus contain desmin and
alpha-smooth muscle actin: relevance for non-sprouting angiogenesis. Histo-
chem. Cell Biol. 130, 1027–1040.
Lee, B.C., Lee, T.H., Avraham, S., and Avraham, H.K. (2004). Involvement of
the chemokine receptor CXCR4 and its ligand stromal cell-derived factor
1alpha in breast cancer cell migration through human brain microvascular
endothelial cells. Mol. Cancer Res. 2, 327–338.
Li, J.L., Sainson, R.C., Shi, W., Leek, R., Harrington, L.S., Preusser, M., Bis-
was, S., Turley, H., Heikamp, E., Hainfellner, J.A., and Harris, A.L. (2007).
Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor
vascular function, and promotes tumor growth in vivo. Cancer Res. 67,
11244–11253.
Lobov, I.B., Brooks, P.C., and Lang, R.A. (2002). Angiopoietin-2 displays
VEGF-dependent modulation of capillary structure and endothelial cell survival
in vivo. Proc. Natl. Acad. Sci. USA 99, 11205–11210.
Lu, C., Kamat, A.A., Lin, Y.G., Merritt, W.M., Landen, C.N., Kim, T.J., Span-
nuth, W., Arumugam, T., Han, L.Y., Jennings, N.B., et al. (2007). Dual targeting
of endothelial cells and pericytes in antivascular therapy for ovarian carci-
noma. Clin. Cancer Res. 13, 4209–4217.
Mazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L.S.,
Gentner, B., Brown, J.L., Naldini, L., and De Palma, M. (2011). Targeting the
ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogen-
esis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19,
512–526.
Mukherjee, D., and Zhao, J. (2013). The Role of chemokine receptor
CXCR4 in breast cancer metastasis. American journal of cancer research
3, 46–57.
Mu¨ller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E.,
McClanahan, T., Murphy, E., Yuan,W.,Wagner, S.N., et al. (2001). Involvement
of chemokine receptors in breast cancer metastasis. Nature 410, 50–56.
Nasarre, P., Thomas, M., Kruse, K., Helfrich, I., Wolter, V., Deppermann, C.,
Schadendorf, D., Thurston, G., Fiedler, U., and Augustin, H.G. (2009). Host-
derived angiopoietin-2 affects early stages of tumor development and vessel
maturation but is dispensable for later stages of tumor growth. Cancer Res.
69, 1324–1333.1080 Cell Reports 10, 1066–1081, February 24, 2015 ª2015 The AuthO’Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M.,
Lane, W.S., Cao, Y., Sage, E.H., and Folkman, J. (1994). Angiostatin: a novel
angiogenesis inhibitor that mediates the suppression of metastases by a Lewis
lung carcinoma. Cell 79, 315–328.
O’Reilly, M.S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W.S., Flynn,
E., Birkhead, J.R., Olsen, B.R., and Folkman, J. (1997). Endostatin: an endog-
enous inhibitor of angiogenesis and tumor growth. Cell 88, 277–285.
Oh, H., Takagi, H., Suzuma, K., Otani, A., Matsumura, M., and Honda, Y.
(1999). Hypoxia and vascular endothelial growth factor selectively up-regulate
angiopoietin-2 in bovine microvascular endothelial cells. J. Biol. Chem. 274,
15732–15739.
Orlidge, A., and D’Amore, P.A. (1987). Inhibition of capillary endothelial cell
growth by pericytes and smooth muscle cells. J. Cell Biol. 105, 1455–1462.
Pa`ez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Vin˜als, F., In-
oue, M., Bergers, G., Hanahan, D., and Casanovas, O. (2009). Antiangiogenic
therapy elicits malignant progression of tumors to increased local invasion and
distant metastasis. Cancer Cell 15, 220–231.
Rigamonti, N., Kadioglu, E., Keklikoglou, I., Wyser Rmili, C., Leow, C.C., and
De Palma, M. (2014). Role of angiopoietin-2 in adaptive tumor resistance to
VEGF signaling blockade. Cell Rep. 8, 696–706.
Saharinen, P., Eklund, L., Pulkki, K., Bono, P., and Alitalo, K. (2011). VEGF and
angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol.
Med. 17, 347–362.
Scharpfenecker, M., Fiedler, U., Reiss, Y., and Augustin, H.G. (2005). The Tie-2
ligand angiopoietin-2 destabilizes quiescent endothelium through an internal
autocrine loop mechanism. J. Cell Sci. 118, 771–780.
Sennino, B., Falco´n, B.L., McCauley, D., Le, T., McCauley, T., Kurz, J.C.,
Haskell, A., Epstein, D.M., and McDonald, D.M. (2007). Sequential loss of
tumor vessel pericytes and endothelial cells after inhibition of platelet-
derived growth factor B by selective aptamer AX102. Cancer Res. 67,
7358–7367.
Skuli, N., Liu, L., Runge, A., Wang, T., Yuan, L., Patel, S., Iruela-Arispe, L.,
Simon, M.C., and Keith, B. (2009). Endothelial deletion of hypoxia-inducible
factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis.
Blood 114, 469–477.
Skuli, N., Majmundar, A.J., Krock, B.L., Mesquita, R.C., Mathew, L.K., Quinn,
Z.L., Runge, A., Liu, L., Kim, M.N., Liang, J., et al. (2012). Endothelial HIF-2a
regulates murine pathological angiogenesis and revascularization processes.
J. Clin. Invest. 122, 1427–1443.
Song, S., Ewald, A.J., Stallcup, W., Werb, Z., and Bergers, G. (2005).
PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differ-
entiation and vascular survival. Nat. Cell Biol. 7, 870–879.
Srivastava, K., Hu, J., Korn, C., Savant, S., Teichert, M., Kapel, S.S., Jugold,
M., Besemfelder, E., Thomas, M., Pasparakis, M., and Augustin, H.G. (2014).
Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2
and metronomic chemotherapy limits metastatic growth. Cancer Cell 26,
880–895.
Stahl, A., Connor, K.M., Sapieha, P., Chen, J., Dennison, R.J., Krah, N.M.,
Seaward, M.R., Willett, K.L., Aderman, C.M., Guerin, K.I., et al. (2010). The
mouse retina as an angiogenesis model. Invest. Ophthalmol. Vis. Sci. 51,
2813–2826.
Strasser, G.A., Kaminker, J.S., and Tessier-Lavigne, M. (2010). Microarray
analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip
cell morphology and branching. Blood 115, 5102–5110.
Suri, C., McClain, J., Thurston, G., McDonald, D.M., Zhou, H., Oldmixon, E.H.,
Sato, T.N., and Yancopoulos, G.D. (1998). Increased vascularization in mice
overexpressing angiopoietin-1. Science 282, 468–471.
Szarvas, T., Ja¨ger, T., To¨tsch, M., vom Dorp, F., Kempkensteffen, C., Ko-
valszky, I., Romics, I., Ergu¨n, S., and Ru¨bben, H. (2008). Angiogenic switch
of angiopietins-Tie2 system and its prognostic value in bladder cancer. Clin.
Cancer Res. 14, 8253–8262.
Thomas, M., and Augustin, H.G. (2009). The role of the Angiopoietins in
vascular morphogenesis. Angiogenesis 12, 125–137.ors
Thomas, M., Kienast, Y., Scheuer, W., Ba¨hner, M., Kaluza, K., Gassner, C.,
Herting, F., Brinkmann, U., Seeber, S., Kavlie, A., et al. (2013). A novel
angiopoietin-2 selective fully human antibody with potent anti-tumoral and
anti-angiogenic efficacy and superior side effect profile compared to Pan-
Angiopoietin-1/-2 inhibitors. PLoS ONE 8, e54923.
Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T.N., Yancopoulos, G.D.,
and McDonald, D.M. (1999). Leakage-resistant blood vessels in mice trans-
genically overexpressing angiopoietin-1. Science 286, 2511–2514.
Thurston, G., Rudge, J.S., Ioffe, E., Zhou, H., Ross, L., Croll, S.D., Glazer, N.,
Holash, J., McDonald, D.M., and Yancopoulos, G.D. (2000). Angiopoietin-1
protects the adult vasculature against plasma leakage. Nat. Med. 6, 460–463.Cell RVasudev, N.S., and Reynolds, A.R. (2014). Anti-angiogenic therapy for cancer:
current progress, unresolved questions and future directions. Angiogenesis
17, 471–494. http://dx.doi.org/10.1007/s10456-014-9420-y.
von Tell, D., Armulik, A., and Betsholtz, C. (2006). Pericytes and vascular sta-
bility. Exp. Cell Res. 312, 623–629.
Weidner, N., Semple, J.P., Welch, W.R., and Folkman, J. (1991). Tumor angio-
genesis and metastasis—correlation in invasive breast carcinoma. N. Engl. J.
Med. 324, 1–8.
Zetter, B.R. (1998). Angiogenesis and tumor metastasis. Annu. Rev. Med. 49,
407–424.eports 10, 1066–1081, February 24, 2015 ª2015 The Authors 1081
